Genetics company RainDance Technologies has withdrawn its IPO registration due to market conditions. The company, which provides genomics tools designed to enable research of non-invasive liquid biopsy applications for early cancer detection, had planned to list shares on the NASDAQ under the symbol RAIN. RainDance's revenues had grown from $17.2 million in 2013 to $30.6 million last year, with its net loss decreasing by $5.5 million in that same period. In February 2014, RainDance raised $42 million in equity and received a valuation of $132 million. Its VC investors include Mohr Davidow Ventures (34.4% stake), Quaker BioVentures (18.5%) and Alloy Ventures (13.3%).